0
Your cart

Your cart is empty

Browse All Departments
  • All Departments
Price
  • R5,000 - R10,000 (2)
  • -
Status
Brand

Showing 1 - 2 of 2 matches in All Departments

Anticancer Drug Resistance - Advances in Molecular and Clinical Research (Hardcover, 1994 ed.): Lori J. Goldstein, Robert F.... Anticancer Drug Resistance - Advances in Molecular and Clinical Research (Hardcover, 1994 ed.)
Lori J. Goldstein, Robert F. Ozols
R5,474 Discovery Miles 54 740 Ships in 10 - 15 working days

Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomenon of drug resistance is largely responsible for these failures and continues to be an area of active investigation. Since the last volume in this series, we have learned that the energy-dependent drug efflux protein, p-glycoprotein, encoded by the MDR 1 gene, is a member of a family of structurally related transport polypeptides, thus allowing us to explore the relationship between structure and function. In addition to ongoing well designed clinical trials aimed at reversing MDR mediated drug resistance, the first gene therapy studies with the MDR 1 gene retrovirally transduced into human bone marrow cells are about to be initiated. Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance. It is clear that drug resistance is complex, and many mechanisms exist by which cancer cells may overcome the cytotoxicity of our known chemotherapeutic agents. As our understanding of each of these mechanisms expands, well designed models will be necessary to test laboratory hypotheses and determine their relationship to drug resistance in humans. It is this integration of basic science and clinical investigation that will both advance our scientific knowledge and result in the improvement of cancer therapy.

Anticancer Drug Resistance - Advances in Molecular and Clinical Research (Paperback, Softcover reprint of the original 1st ed.... Anticancer Drug Resistance - Advances in Molecular and Clinical Research (Paperback, Softcover reprint of the original 1st ed. 1994)
Lori J. Goldstein, Robert F. Ozols
R5,433 Discovery Miles 54 330 Ships in 10 - 15 working days

Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomenon of drug resistance is largely responsible for these failures and continues to be an area of active investigation. Since the last volume in this series, we have learned that the energy-dependent drug efflux protein, p-glycoprotein, encoded by the MDR 1 gene, is a member of a family of structurally related transport polypeptides, thus allowing us to explore the relationship between structure and function. In addition to ongoing well designed clinical trials aimed at reversing MDR mediated drug resistance, the first gene therapy studies with the MDR 1 gene retrovirally transduced into human bone marrow cells are about to be initiated. Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance. It is clear that drug resistance is complex, and many mechanisms exist by which cancer cells may overcome the cytotoxicity of our known chemotherapeutic agents. As our understanding of each of these mechanisms expands, well designed models will be necessary to test laboratory hypotheses and determine their relationship to drug resistance in humans. It is this integration of basic science and clinical investigation that will both advance our scientific knowledge and result in the improvement of cancer therapy.

Free Delivery
Pinterest Twitter Facebook Google+
You may like...
Dala A2 Sketch Pad (120gsm)(36 Sheets)
R260 Discovery Miles 2 600
Meet The Moonlight
Jack Johnson CD R405 Discovery Miles 4 050
Nintendo Labo Customisation Set for…
R246 R114 Discovery Miles 1 140
Astrum MU100 USB Optical Mouse (Black)
R79 Discovery Miles 790
Loot
Nadine Gordimer Paperback  (2)
R383 R310 Discovery Miles 3 100
Home Classix Trusty Traveller Mug…
R99 R81 Discovery Miles 810
Casio LW-200-7AV Watch with 10-Year…
R999 R884 Discovery Miles 8 840
Tenet
John David Washington, Robert Pattinson, … DVD  (1)
R51 Discovery Miles 510
Loot
Nadine Gordimer Paperback  (2)
R383 R310 Discovery Miles 3 100
Huntlea Koletto - Matlow Pet Bed…
R969 R562 Discovery Miles 5 620

 

Partners